http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-102021023010-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac73ee5e8c91acf9c198babff125ce32 |
| classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K135-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-16 |
| filingDate | 2021-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c8cf2ce7149b770465d0528c798c9cee http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7c53ca0b88807f97b83d026ff031d46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b12d006399ae5d83ffed607bb3c2c38b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c81ada305b483a8efbe3b5bb98fab553 |
| publicationDate | 2022-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | BR-102021023010-A2 |
| titleOfInvention | Nanoformulation based on fixed oil of croton cajucara benth developed for oral use with associated action in the treatment of pain and inflammation |
| abstract | Nanoformulation based on fixed oil of croton cajucara benth developed for oral use with associated action in the treatment of pain and inflammation. In the present invention, a snedds system (self-nanoemulsifying drug delivery system) was used to encapsulate the fixed oil extracted from the bark of the croton cajucara benth (ofcc) stem. the nanoformulation called snedds-ofcc corresponds to the snedds carrier containing 15 mg of ofcc, which has mostly sesquiterpenes (spathulenol, cyperene, ¿-copaene, ¿-cadinene, viridiflorol and cis-caryophyllene) and to a lesser extent, linalool, mixtures of sterols and fatty acids, and the diterpenes trans-crotonin, cis-cajucarin b and trans-cajucarin b. the snedds carrier, formed through a moderate heating process by homogenizing the oil/water phases, contains reduced percentages of the surfactant (7 to 12% of the tween 40 and tween 80 mixture), an oil for food use (0.5 to 2%) and distilled (or double-distilled) water in a high percentage (92.5 to 86%). the therapeutic efficacy of the co-surfactant-free snedds-ofcc invention, containing encapsulated focc in low concentration (15 mg), was evaluated in vivo, v.o., in pain and inflammation processes. the phytotherapic snedds-ofcc showed significant results that made it possible to indicate its use in the treatment of inflammatory pathologies. the search for formulations from natural sources that exert associated therapeutic effects and minimize possible adverse effects, are stable and can be reproduced on a large scale, justifies the importance of developing new drugs. |
| priorityDate | 2021-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.